Stock A261780 CHA VACCINE RESEARCH INSTITUTE
Add to a list
To use this feature you must be a member
Log inSign up

Financials CHA Vaccine Research Institute

Equities

A261780

KR7261780001

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-29 pm EDT 		5-day change 1st Jan Change
4,680 KRW +0.11% Intraday chart for CHA Vaccine Research Institute -0.85% -17.17%
Jan. 08 CHA Biotech to Partner with Subsidiary to Advance NK Cell Therapy MT
2023 Cha Vaccine Research Institute Co., Ltd. announced that it has received KRW 10 billion in funding from EBEST Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 293,364 131,749 151,036
Enterprise Value (EV) 1 252,660 97,624 116,467
P/E ratio -14.1 x -19.6 x -86 x
Yield - - -
Capitalization / Revenue 587 x 734 x 514 x
EV / Revenue 505 x 544 x 396 x
EV / EBITDA -43.3 x -16.1 x -19.8 x
EV / FCF -41.9 x -14.4 x -11.4 x
FCF Yield -2.39% -6.96% -8.8%
Price to Book 7.41 x 3.95 x 4.26 x
Nbr of stocks (in thousands) 26,429 26,429 26,732
Reference price 2 11,100 4,985 5,650
Announcement Date 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 500 179.5 294.1
EBITDA 1 -5,839 -6,052 -5,886
EBIT 1 -6,085 -6,469 -6,419
Operating Margin -1,216.93% -3,604.36% -2,182.53%
Earnings before Tax (EBT) 1 -18,420 -6,715 -2,103
Net income 1 -18,420 -6,715 -1,749
Net margin -3,684.01% -3,741.36% -594.82%
EPS 2 -789.6 -254.1 -65.72
Free Cash Flow 1 -6,029 -6,799 -10,251
FCF margin -1,205.81% -3,787.96% -3,485.32%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 - - -
Net Cash position 1 40,704 34,125 34,569
Leverage (Debt/EBITDA) - - -
Free Cash Flow 1 -6,029 -6,799 -10,251
ROE (net income / shareholders' equity) -89.4% -18.4% -5.09%
ROA (Net income/ Total Assets) -8.35% -6.4% -7.56%
Assets 1 220,534 104,949 23,152
Book Value Per Share 2 1,499 1,262 1,325
Cash Flow per Share 2 150.0 90.30 221.0
Capex 1 680 447 279
Capex / Sales 135.91% 249.27% 94.71%
Announcement Date 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CHA VACCINE RESEARCH INSTITUTE Stock CHA Vaccine Research Institute
-17.17% 91.06M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+8.92% 114B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.48% 105B
ARGENX SE Stock argenx SE
-2.71% 21.73B
BIONTECH SE Stock BioNTech SE
-6.45% 23.83B
GENMAB A/S Stock Genmab A/S
-10.63% 18.1B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.36% 16.34B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.45% 16.13B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.76% 13.75B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.94% 11.76B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A261780 Stock
  4. Financials CHA Vaccine Research Institute